手术前期化疗治疗胃和胃食管交界处（G/GEJ）腺癌比单独手术可以提供生存益处，但结果需要改进。本研究旨在评估靶向药物西妥昔单抗联合5-氟尿嘧啶和顺铂预防性化疗的疗效和安全性。患者在手术前和术后接受6个周期的西妥昔单抗、顺铂和简化LV5FU2。主要目的是对肿瘤客观反应（TOR）进行综合评估，评估方法是通过计算机断层扫描，而且无重度毒性导致预防性化疗（NCT）的中断（分别为45％和90％）。从2011年至2013年，共招募了65名患者。从64名可评估主要终点的患者中，19名（29.7％）具有形态学TOR，而61名（95.3％）由于重大毒性未在预防性化疗过程中提前停止。60名患者（92.3％）接受了手术。16名患者（56可用，占28.5％）具有组织学反应（Mandard肿瘤回归分级≤3）。经过44.5个月的中位随访后，中位无病生存期和总生存期分别为24.4个月[95％CI：16.4-39.4]和40.3个月[95％CI：27.5-NA]。在可手术的G/GEJ腺癌中添加西妥昔单抗到NCT方案中是安全的，但在本研究中并没有显示出足够的疗效来满足主要终点（NCT01360086）。

While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the efficacy and safety of perioperative cetuximab combined with 5-fluorouracil and cisplatin.Patients received six cycles of cetuximab, cisplatin, and simplified LV5FU2 before and after surgery. The primary objective was a combined evaluation of the tumor objective response (TOR), assessed by computed tomography, and the absence of major toxicities resulting in discontinuation of neoadjuvant chemotherapy (NCT) (45% and 90%, respectively).From 2011 to 2013, 65 patients were enrolled. From 64 patients evaluable for the primary endpoint, 19 (29.7%) had a morphological TOR and 61 (95.3%) did not stop NCT prematurely due to major toxicity. Sixty patients (92.3%) underwent resection. Sixteen patients (/56 available, 28.5%) had histological responses (Mandard tumor regression grade ≤3). After a median follow-up of 44.5 months, median disease-free and overall survival were 24.4 [95% CI: 16.4-39.4] and 40.3 months [95% CI: 27.5-NA], respectively.Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086).